Chronic Disease ; Heart Failure ; Humans

Background: Heart failure is a common clinical condition and is the late stage of most cardiovascular diseases. Heart rate disorder is one of the causes of deaths in patients with chronic heart failure. There is few number of studies on Heart Rate Variability (HRV) in Vietnam. Objective: To study the change of HRV time in patients with chronic heart failure. Subject and Method: A prospective, descriptive and cross-sectional study was carried out on 105 subjects including 73 patients with chronic heart failure and 42 normal persons as controls. Time domain measurements of HRV were calculated from 24 hour electrocardiographic Holter (Holter WIN P-V, USA) on all 105 subjects. In the chronic heart failure group, there were 51 men and 22 women with the mean age of 62.8+/-11.2, control group including 30 men and 12 women with the mean age of 61.5+/-5.7. Results and conclusion: (1) There was a decrease of time domain of HRV showed the decrease of parasympathetic tone in patients with chronic heart diseases. (2) The higher degree of heart failure, the lower the time domain of HRV.
Chronic heart disease ; heart rate variability

BACKGROUND AND OBJECTIVES: The utility of Doppler mitral flow pattems for the indirect assessment of left ventricular diastolic function is valid and widely used. One of the most common variables affecting mitral flow is heart rate. The aim of this study was to compare between mitral flow and mitral annulus velocity by Doppler tissue imaging (DTI) according to increment of heart rate. MATERIALS AND METHODS: 17 healthy volunteers (M: F=10: 7, mean age 27+/-2 years) comprised this study. They were free of any acute or chronic illness. The heart rate was elevated by increments of 10 beats (baseline, 80, 90, 100, 110, 120) by transesophageal atrial pacing. We measured mitral flow parameters (E and A velocity, E/A ratio, IVRT, DT of E) and mitral annulus velocity by DTI (e and a velocity, e/a ratio, RIVRT). We gave the score of visual estimation at baseline and each heart rate. The definition of the score was as follows, 1: well visualization of each envelope 2: summation of velocity wave forms 3: no differentiation, completely fused. RESULTS: 1) The E of mitral flow was significantly increased from 100 to 120 BPM and A velocity was significantly increased from 80 to 100 BPM (p<0.05). E/A ratio was significantly decreased from 90 to 100 BPM than baseline (p<0.05). 2) The e and e/a ratio of mitral annulus velocity were significantly increased from above 110, 100 BPM than baseline, respectively (p<0.05). But a velocity was little changed. 3) The score was all significantly higher in mitral annulus velocity pattern by DTI than mitral flow at each heart rate. CONCLUSIONS: The mitral annulus velocity by DTI is less affected by heart rate and visualized better than mitral fiow in increased heart rate. Therefore the assessment of mitral annulus velocity may be helpful for evaluating diastolic function during heart rates of physiologic range.
Chronic Disease ; Healthy Volunteers ; Heart Rate* ; Heart*

Chronic Disease ; Heart Failure ; Humans ; Nutrition Assessment

Chronic Disease ; Heart Failure ; drug therapy ; Humans

Objective: To analyze the changes on gut microbiota and metabolic products in patients with chronic heart failure. Methods: By searching the Pubmed, EMBASE, Cochrane Library, and CNKI, Wanfang, and CMB databases from the day of built up to December 2019, we screened related literature exploring the intestinal flora of chronic heart failure patients, and systematic review was performed to study changes in intestinal flora composition, function, and metabolites among chronic heart failure patients. Results: A total of 10 articles were included to study the gut microbiota of patients with chronic heart failure in this analysis. The systematic review showed significant changes in β-diversity in patients with heart failure. The abundance of faecalibacterium, blautia, bacteroides, prevotella and anaerostipes was decreased, while the abundance of streptococcus, escherichia/shigella, veillonella, and enterobacte was increased. The increased microbial gene function in patients with heart failure included tryptophan metabolism, lipid metabolism, LPS synthesis,and so on, especially, bacterial genes related to trimethylamine oxide production increased significantly, while genes related to key enzymes producing the beneficial metabolite butyrate decreased significantly, and harmful metabolite trimethylamine oxide levels increased in chronic heart failure patients. Conclusion: There are significant changes in the structure, function and metabolites of intestinal flora in patients with chronic heart failure.
Chronic Disease ; Gastrointestinal Microbiome ; Heart Failure ; Humans

Chronic Disease ; Heart Failure ; therapy ; Heart Rate ; Humans

Chronic Disease ; Heart Failure ; therapy ; Heart Rate ; Humans

No abstract available.
Pulmonary Disease, Chronic Obstructive* ; Pulmonary Heart Disease* ; Tuberculosis, Pulmonary*

Heart failure (HF),a chronic progressive disease,is a global health problem and the leading cause of deaths in the global population.The pathophysiological abnormalities of HF mainly include abnormal cardiac structure (myocardium and valves),disturbance of electrophysiological activities,and weakened myocardial contractility.In addition to drug therapy and heart transplantation,interventional therapies can be employed for advanced-stage HF,including transcatheter interventions and mechanical circulatory assist devices.This article introduces the devices used for advanced HF that have been marketed or certified as innovative or breakthrough devices around the world and summarizes the research status and prospects the trend in this field.As diversified combinations of HF devices are used for the treatment of advanced HF,considerations regarding individualized HF therapy,risk-benefit evaluation on device design,medical insurance payment,post-market supervision system,and protection of intellectual property rights of high-end technology are needed,which will boost the development of the technology and industry and benefit the patients.
Humans ; Heart-Assist Devices ; Heart Failure/therapy* ; Heart Transplantation ; Myocardium ; Chronic Disease